Liver Cancer (Hepatoma / Hepatocellular Carcinoma / HCC) Clinical Trials

California Pacific CURRENTS: The online journal of CPMC Research Institute

First Line Treatment

A Randomized, Multi-center Phase III Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (CheckMate 459: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 459)

Description: The purpose of this study is to determine if nivolumab or sorafenib is more effective in the treatment of Advanced Hepatocellular Carcinoma

Investigators

Eligibility Requirements

Subjects 18 y/o and older, with histologically confirmed advanced hepatocellular carcinoma, not eligible for surgical and/or locoregional therapies; or progressive disease after surgical and /or locoregional therapies

Status

Active and open to enrollment

Contacts

Brenda Eng, 415-600-1775

 

Second Line Treatment

A Phase 1b/2 Dose Escalation and Expansion Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients With Advanced Solid Tumors or Non-Small Cell Lung, Biliary Tract, and Bladder Cancer  (NCT02240238)

Description: Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer
 

Investigators

Eligibility Requirements

Subjects, 18 y/o and older, who have a histologically or cytologically confirmed diagnosis of advanced solid tumor that has relapsed or is refractory to standard curative or palliative therapy or has a contraindication to standard therapy; or who have histologically or cytologically confirmed diagnosis of Stage IIIB or IV NSCLC and have received 1 or 2 lines of prior chemotherapy or targeted therapy for Stage IIIB or IV NSCLC (second- or third-line)

Status

Active and open to enrollment

Contacts

Leslie Corona, 415-600-5766

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma

Description: The purpose of the study is to evaluate the efficacy of enzalutamide in subjects with advanced hepatocellular carcinoma (HCC) as measured by overall survival (OS)

Investigators

Eligibility Requirements

Subjects 18 y/o and older, with a documented diagnosis of advanced HCC of any etiology

Status

Active and open to enrollment

Contacts

Brenda Eng, 415-600-1775

 

Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein Following First-Line Therapy With Sorafenib

Description: The purpose of this study is to evaluate the safety and efficacy of ramucirumab in participants with hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein

Investigators

Eligibility Requirements

Subjects 18 y/o and older, with a diagnosis of HCC based on histopathologic findings, or a diagnosis of cirrhosis and a tumor with classical HCC imaging characteristics

Status

Active and open to enrollment

Contacts

Brenda Eng, 415-600-1775

 

A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects With Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240)

Description: This is a study of pembrolizumab (MK-3475) in participants with previously systemically treated advanced hepatocellular carcinoma (HCC)

Investigators

Eligibility Requirements

Subjects 18 y/o and older, with an HCC diagnosis confirmed by radiology, histology or cytology (fibrolamellar and mixed hepatocellular/cholangiocarcinoma subtypes are not eligible)

Status

Active and open to enrollment

Contacts

Brenda Eng, 415-600-1775

A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib

Description: Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib (CELESTIAL)

Investigators

Eligibility Requirements

Subjects 18 y/o and older, who have a Histological or cytological diagnosis of HCC

Status

Active and open to enrollment

Contacts

Brenda Eng, 415-600-1775